COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the Company has identified Gonorrhea as its second bacterial target for treatment with the Company’s EVX-B2 vaccine product candidate.
Read more at globenewswire.comEvaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
